Is Johnson & Johnson (JNJ) undervalued? · P/E 17, rev $49.37B
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
This page asks whether Johnson & Johnson (JNJ) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
JNJ currently screens at market cap $375.37B and trailing P/E 17.4. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new JNJ 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare JNJ to the stock page model before you treat a low multiple as a gift.
Not investment advice.